Female Sexual Dysfunction Affects Millions of Women and Gets Almost No Clinical Attention

Last updated: 15/07/2026 quarta-feira

Between 38% and 63% of women experience some form of sexual dysfunction at some point in their lives, depending on which body of research you consult. Yet, despite this representing a significant portion of the female population, across age groups, health backgrounds, and relationship contexts, the condition remains one of the most underreported and undertreated in women’s health.

The reasons are connected to social stigma, limited training among healthcare providers, and patient reluctance to raise the topic, which combine to create a situation where the majority of affected women never receive a clinical evaluation or a treatment plan. A 2024 study published in the Journal of Family Medicine and Primary Care found that most doctors feel undertrained and uncomfortable initiating conversations about female sexual dysfunction, which means the burden of disclosure falls entirely on the patient, and most patients don’t carry it.

What Female Sexual Dysfunction Covers

The clinical definition of female sexual dysfunction encompasses several distinct but often overlapping conditions: low sexual desire, difficulty with arousal, inability to reach orgasm, pain during intercourse, and inadequate lubrication. These can occur independently or together, and their causes are equally varied.

Hormonal changes are among the most common drivers. As estrogen and testosterone levels shift during perimenopause, menopause, the postpartum period, or as a result of hormonal contraception, the effects on libido, tissue health, and arousal can be significant. Vaginal dryness, reduced sensation, and pain during intercourse are frequently tied to declining estrogen, which thins and reduces elasticity in vaginal tissues over time.

Neurological and circulatory factors also play a role. Adequate blood flow to genital tissue is necessary for arousal and sensation, and conditions that affect vascular health, including diabetes, cardiovascular disease, and certain medications, can reduce it. Psychological factors, including stress, anxiety, depression, and relationship dynamics, are equally relevant. Sexual function is not purely mechanical, and any honest clinical evaluation accounts for all of these dimensions.

The Gap Between Prevalence and Treatment

One of the more consequential aspects of the underdiagnosis problem is that female sexual dysfunction tends to worsen when left unaddressed. Hormonal changes progress, tissue changes compound, and the psychological weight of experiencing ongoing sexual difficulty without explanation or support adds its own layer. Women who do seek help often report doing so only after years of assuming the symptoms were either normal or untreatable.

The contrast with men’s sexual health is stark. Erectile dysfunction has a well-established clinical pathway, a range of approved treatments, and a cultural conversation that, however imperfect, exists. Female sexual dysfunction has no equivalent. The absence of FDA-approved testosterone therapies for women, despite decades of evidence supporting testosterone’s role in female libido and sexual function, illustrates the gap clearly.

Where Regenerative Approaches Fit In

For women whose sexual dysfunction has a tissue-based or vascular component, regenerative medicine offers a different category of option. The O-Shot is a platelet-rich plasma (PRP) injection procedure targeting vaginal and clitoral tissue, using growth factors derived from your own blood to support tissue repair, improve circulation, and stimulate cellular regeneration in the treated area.

The clinical evidence is still developing. Studies to date have been largely small and observational, and the research community has consistently called for larger, controlled trials to fully characterize outcomes. What the available data does show is that PRP in this context has a strong safety profile, with no significant adverse events reported across studies, and that patients in published trials have reported improvements in lubrication, sensitivity, arousal, and orgasm function. A 2024-2025 randomized controlled trial comparing intravaginal PRP to vaginal estriol therapy in postmenopausal women found significant improvements in female sexual function index scores and vaginal health markers in both groups, with the PRP group showing slightly greater gains.

The O-Shot is best understood as an emerging treatment for women who have not responded to conventional approaches, or who are looking for a non-hormonal regenerative option to address tissue-level changes. It is not a first-line standard of care, and a thorough evaluation is the appropriate starting point to determine whether it’s indicated.

What a Physician-Led Evaluation Changes

The most important thing a clinical evaluation does is identify the specific drivers behind the dysfunction. Low libido tied to testosterone decline responds differently than pain caused by vaginal atrophy, which responds differently than arousal difficulty tied to circulatory factors. Conflating them leads to treatment that doesn’t address the actual problem.

At Noor Esthetique and Wellness Center, female sexual health is approached as what it is: a medical concern with multiple potential causes and a growing range of evidence-based options to address them. The starting point is always a comprehensive evaluation, so that any intervention reflects what’s actually driving the experience.

If you’ve been living with changes in your sexual health and haven’t found a clinical space to address them, that conversation is available here. Book a consultation at glowwithnoor.com.